Abiomed, Inc. (ABMD) Stock Competitors & Peer Comparison
See (ABMD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABMD | $381.02 | +0.00% | 17.2B | 65.36 | $5.83 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $89.73 | +3.17% | 151.5B | 24.37 | $3.57 | +2.80% |
| ISRG | $417.46 | +3.77% | 144.2B | 49.37 | $8.25 | N/A |
| SYK | $299.18 | +2.00% | 113.1B | 34.11 | $8.65 | +1.17% |
| MDT | $81.36 | +10.32% | 100.2B | 21.80 | $3.58 | +3.66% |
| BSX | $48.64 | +2.00% | 70.9B | 19.96 | $2.39 | N/A |
| BRKRP | $445.17 | +4.03% | 70.4B | N/A | N/A | +0.33% |
| EW | $87.56 | -0.11% | 49.5B | 46.51 | $1.85 | N/A |
| DXCM | $72.42 | -1.40% | 28.1B | 31.23 | $2.33 | N/A |
Stock Comparison
ABMD vs BSX-PA Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ABMD is priced at $381.02, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ABMD's ROE is +0.10%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ABMD is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check BSX-PA's competition here
ABMD vs ABT Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ABT has a market cap of 151.5B. Regarding current trading prices, ABMD is priced at $381.02, while ABT trades at $89.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ABT's P/E ratio is 24.37. In terms of profitability, ABMD's ROE is +0.10%, compared to ABT's ROE of +0.12%. Regarding short-term risk, ABMD is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check ABT's competition here
ABMD vs ISRG Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ISRG has a market cap of 144.2B. Regarding current trading prices, ABMD is priced at $381.02, while ISRG trades at $417.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ISRG's P/E ratio is 49.37. In terms of profitability, ABMD's ROE is +0.10%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, ABMD is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check ISRG's competition here
ABMD vs SYK Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SYK has a market cap of 113.1B. Regarding current trading prices, ABMD is priced at $381.02, while SYK trades at $299.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SYK's P/E ratio is 34.11. In terms of profitability, ABMD's ROE is +0.10%, compared to SYK's ROE of +0.15%. Regarding short-term risk, ABMD is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check SYK's competition here
ABMD vs MDT Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, MDT has a market cap of 100.2B. Regarding current trading prices, ABMD is priced at $381.02, while MDT trades at $81.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas MDT's P/E ratio is 21.80. In terms of profitability, ABMD's ROE is +0.10%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ABMD is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check MDT's competition here
ABMD vs BSX Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BSX has a market cap of 70.9B. Regarding current trading prices, ABMD is priced at $381.02, while BSX trades at $48.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BSX's P/E ratio is 19.96. In terms of profitability, ABMD's ROE is +0.10%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ABMD is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check BSX's competition here
ABMD vs BRKRP Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BRKRP has a market cap of 70.4B. Regarding current trading prices, ABMD is priced at $381.02, while BRKRP trades at $445.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BRKRP's P/E ratio is N/A. In terms of profitability, ABMD's ROE is +0.10%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, ABMD is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check BRKRP's competition here
ABMD vs EW Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, EW has a market cap of 49.5B. Regarding current trading prices, ABMD is priced at $381.02, while EW trades at $87.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas EW's P/E ratio is 46.51. In terms of profitability, ABMD's ROE is +0.10%, compared to EW's ROE of +0.11%. Regarding short-term risk, ABMD is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check EW's competition here
ABMD vs DXCM Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, DXCM has a market cap of 28.1B. Regarding current trading prices, ABMD is priced at $381.02, while DXCM trades at $72.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas DXCM's P/E ratio is 31.23. In terms of profitability, ABMD's ROE is +0.10%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, ABMD is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check DXCM's competition here
ABMD vs RMD Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, RMD has a market cap of 27.1B. Regarding current trading prices, ABMD is priced at $381.02, while RMD trades at $190.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas RMD's P/E ratio is 17.98. In terms of profitability, ABMD's ROE is +0.10%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ABMD is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check RMD's competition here
ABMD vs PHG Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PHG has a market cap of 24.1B. Regarding current trading prices, ABMD is priced at $381.02, while PHG trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PHG's P/E ratio is 21.86. In terms of profitability, ABMD's ROE is +0.10%, compared to PHG's ROE of +0.09%. Regarding short-term risk, ABMD is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check PHG's competition here
ABMD vs STE Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, STE has a market cap of 20.6B. Regarding current trading prices, ABMD is priced at $381.02, while STE trades at $212.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas STE's P/E ratio is 26.52. In terms of profitability, ABMD's ROE is +0.10%, compared to STE's ROE of +0.11%. Regarding short-term risk, ABMD is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check STE's competition here
ABMD vs ZBH Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ZBH has a market cap of 16.4B. Regarding current trading prices, ABMD is priced at $381.02, while ZBH trades at $86.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ZBH's P/E ratio is 22.02. In terms of profitability, ABMD's ROE is +0.10%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ABMD is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check ZBH's competition here
ABMD vs SNN Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, ABMD is priced at $381.02, while SNN trades at $30.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SNN's P/E ratio is 20.93. In terms of profitability, ABMD's ROE is +0.10%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ABMD is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check SNN's competition here
ABMD vs SWAV Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ABMD is priced at $381.02, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ABMD's ROE is +0.10%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ABMD is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check SWAV's competition here
ABMD vs PEN Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, ABMD is priced at $381.02, while PEN trades at $320.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PEN's P/E ratio is 73.76. In terms of profitability, ABMD's ROE is +0.10%, compared to PEN's ROE of +0.12%. Regarding short-term risk, ABMD is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check PEN's competition here
ABMD vs ALGN Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ALGN has a market cap of 11.6B. Regarding current trading prices, ABMD is priced at $381.02, while ALGN trades at $165.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ALGN's P/E ratio is 27.22. In terms of profitability, ABMD's ROE is +0.10%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, ABMD is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check ALGN's competition here
ABMD vs GMED Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, GMED has a market cap of 10.5B. Regarding current trading prices, ABMD is priced at $381.02, while GMED trades at $79.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas GMED's P/E ratio is 18.21. In terms of profitability, ABMD's ROE is +0.10%, compared to GMED's ROE of +0.13%. Regarding short-term risk, ABMD is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check GMED's competition here
ABMD vs PODD Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PODD has a market cap of 9.9B. Regarding current trading prices, ABMD is priced at $381.02, while PODD trades at $146.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PODD's P/E ratio is 33.48. In terms of profitability, ABMD's ROE is +0.10%, compared to PODD's ROE of +0.21%. Regarding short-term risk, ABMD is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check PODD's competition here
ABMD vs BRKR Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BRKR has a market cap of 9.5B. Regarding current trading prices, ABMD is priced at $381.02, while BRKR trades at $59.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BRKR's P/E ratio is -261.25. In terms of profitability, ABMD's ROE is +0.10%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, ABMD is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check BRKR's competition here
ABMD vs MASI Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ABMD is priced at $381.02, while MASI trades at $178.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas MASI's P/E ratio is 44.36. In terms of profitability, ABMD's ROE is +0.10%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ABMD is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check MASI's competition here
ABMD vs BIO-B Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BIO-B has a market cap of 8.2B. Regarding current trading prices, ABMD is priced at $381.02, while BIO-B trades at $319.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BIO-B's P/E ratio is 50.64. In terms of profitability, ABMD's ROE is +0.10%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, ABMD is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check BIO-B's competition here
ABMD vs BIO Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BIO has a market cap of 8.2B. Regarding current trading prices, ABMD is priced at $381.02, while BIO trades at $307.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BIO's P/E ratio is 50.60. In terms of profitability, ABMD's ROE is +0.10%, compared to BIO's ROE of +0.02%. Regarding short-term risk, ABMD is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check BIO's competition here
ABMD vs GKOS Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, GKOS has a market cap of 6.7B. Regarding current trading prices, ABMD is priced at $381.02, while GKOS trades at $121.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas GKOS's P/E ratio is -34.45. In terms of profitability, ABMD's ROE is +0.10%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, ABMD is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check GKOS's competition here
ABMD vs NARI Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ABMD is priced at $381.02, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas NARI's P/E ratio is -59.24. In terms of profitability, ABMD's ROE is +0.10%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ABMD is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check NARI's competition here
ABMD vs LIVN Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, LIVN has a market cap of 3.9B. Regarding current trading prices, ABMD is priced at $381.02, while LIVN trades at $73.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas LIVN's P/E ratio is 36.39. In terms of profitability, ABMD's ROE is +0.10%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, ABMD is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check LIVN's competition here
ABMD vs AXNX Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ABMD is priced at $381.02, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ABMD's ROE is +0.10%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ABMD is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check AXNX's competition here
ABMD vs IRTC Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, IRTC has a market cap of 3.4B. Regarding current trading prices, ABMD is priced at $381.02, while IRTC trades at $108.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas IRTC's P/E ratio is -123.01. In terms of profitability, ABMD's ROE is +0.10%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, ABMD is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check IRTC's competition here
ABMD vs ITGR Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, ABMD is priced at $381.02, while ITGR trades at $92.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ITGR's P/E ratio is 22.56. In terms of profitability, ABMD's ROE is +0.10%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, ABMD is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check ITGR's competition here
ABMD vs TMDX Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, TMDX has a market cap of 2.4B. Regarding current trading prices, ABMD is priced at $381.02, while TMDX trades at $72.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas TMDX's P/E ratio is 15.95. In terms of profitability, ABMD's ROE is +0.10%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, ABMD is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check TMDX's competition here
ABMD vs AXGN Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, ABMD is priced at $381.02, while AXGN trades at $42.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AXGN's P/E ratio is -63.48. In terms of profitability, ABMD's ROE is +0.10%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, ABMD is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check AXGN's competition here
ABMD vs ESTA Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, ABMD is priced at $381.02, while ESTA trades at $76.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ESTA's P/E ratio is -49.26. In terms of profitability, ABMD's ROE is +0.10%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, ABMD is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check ESTA's competition here
ABMD vs NUVA Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ABMD is priced at $381.02, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ABMD's ROE is +0.10%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ABMD is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check NUVA's competition here
ABMD vs UFPT Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, ABMD is priced at $381.02, while UFPT trades at $226.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas UFPT's P/E ratio is 24.84. In terms of profitability, ABMD's ROE is +0.10%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ABMD is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check UFPT's competition here
ABMD vs PRCT Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, ABMD is priced at $381.02, while PRCT trades at $26.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PRCT's P/E ratio is -14.39. In terms of profitability, ABMD's ROE is +0.10%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, ABMD is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check PRCT's competition here
ABMD vs AHCO Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, ABMD is priced at $381.02, while AHCO trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AHCO's P/E ratio is -16.47. In terms of profitability, ABMD's ROE is +0.10%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, ABMD is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check AHCO's competition here
ABMD vs HSKA Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ABMD is priced at $381.02, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ABMD's ROE is +0.10%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ABMD is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check HSKA's competition here
ABMD vs IART Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, ABMD is priced at $381.02, while IART trades at $17.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas IART's P/E ratio is -2.49. In terms of profitability, ABMD's ROE is +0.10%, compared to IART's ROE of -0.48%. Regarding short-term risk, ABMD is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check IART's competition here
ABMD vs ENOV Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ENOV has a market cap of 1.2B. Regarding current trading prices, ABMD is priced at $381.02, while ENOV trades at $22.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ENOV's P/E ratio is -1.08. In terms of profitability, ABMD's ROE is +0.10%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, ABMD is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check ENOV's competition here
ABMD vs TNDM Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, ABMD is priced at $381.02, while TNDM trades at $19.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas TNDM's P/E ratio is -13.16. In terms of profitability, ABMD's ROE is +0.10%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, ABMD is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check TNDM's competition here
ABMD vs ATEC Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, ABMD is priced at $381.02, while ATEC trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ATEC's P/E ratio is -9.25. In terms of profitability, ABMD's ROE is +0.10%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, ABMD is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check ATEC's competition here
ABMD vs AVNS Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ABMD is priced at $381.02, while AVNS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AVNS's P/E ratio is -15.60. In terms of profitability, ABMD's ROE is +0.10%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ABMD is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check AVNS's competition here
ABMD vs INSP Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, ABMD is priced at $381.02, while INSP trades at $41.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas INSP's P/E ratio is 9.20. In terms of profitability, ABMD's ROE is +0.10%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ABMD is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check INSP's competition here
ABMD vs IRMD Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, ABMD is priced at $381.02, while IRMD trades at $94.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas IRMD's P/E ratio is 49.79. In terms of profitability, ABMD's ROE is +0.10%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, ABMD is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check IRMD's competition here
ABMD vs BFLY Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BFLY has a market cap of 1.1B. Regarding current trading prices, ABMD is priced at $381.02, while BFLY trades at $5.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BFLY's P/E ratio is -14.65. In terms of profitability, ABMD's ROE is +0.10%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, ABMD is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check BFLY's competition here
ABMD vs SILK Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ABMD is priced at $381.02, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SILK's P/E ratio is -18.96. In terms of profitability, ABMD's ROE is +0.10%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ABMD is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check SILK's competition here
ABMD vs FNA Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ABMD is priced at $381.02, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas FNA's P/E ratio is -19.83. In terms of profitability, ABMD's ROE is +0.10%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ABMD is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check FNA's competition here
ABMD vs AORT Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AORT has a market cap of 999.3M. Regarding current trading prices, ABMD is priced at $381.02, while AORT trades at $20.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AORT's P/E ratio is 82.34. In terms of profitability, ABMD's ROE is +0.10%, compared to AORT's ROE of +0.03%. Regarding short-term risk, ABMD is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check AORT's competition here
ABMD vs CNMD Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CNMD has a market cap of 996.5M. Regarding current trading prices, ABMD is priced at $381.02, while CNMD trades at $34.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CNMD's P/E ratio is 18.70. In terms of profitability, ABMD's ROE is +0.10%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, ABMD is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check CNMD's competition here
ABMD vs SSII Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SSII has a market cap of 862.6M. Regarding current trading prices, ABMD is priced at $381.02, while SSII trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SSII's P/E ratio is -86.20. In terms of profitability, ABMD's ROE is +0.10%, compared to SSII's ROE of -0.23%. Regarding short-term risk, ABMD is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check SSII's competition here
ABMD vs INMD Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, INMD has a market cap of 854.7M. Regarding current trading prices, ABMD is priced at $381.02, while INMD trades at $13.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas INMD's P/E ratio is 9.99. In terms of profitability, ABMD's ROE is +0.10%, compared to INMD's ROE of +0.13%. Regarding short-term risk, ABMD is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check INMD's competition here
ABMD vs CSII Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ABMD is priced at $381.02, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CSII's P/E ratio is -20.83. In terms of profitability, ABMD's ROE is +0.10%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ABMD is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check CSII's competition here
ABMD vs LMRI Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, LMRI has a market cap of 746.5M. Regarding current trading prices, ABMD is priced at $381.02, while LMRI trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas LMRI's P/E ratio is -19.92. In terms of profitability, ABMD's ROE is +0.10%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, ABMD is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check LMRI's competition here
ABMD vs CRY Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, ABMD is priced at $381.02, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CRY's P/E ratio is 425.71. In terms of profitability, ABMD's ROE is +0.10%, compared to CRY's ROE of +0.03%. Regarding short-term risk, ABMD is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check CRY's competition here
ABMD vs CBLL Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CBLL has a market cap of 651.9M. Regarding current trading prices, ABMD is priced at $381.02, while CBLL trades at $18.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CBLL's P/E ratio is -10.60. In terms of profitability, ABMD's ROE is +0.10%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, ABMD is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check CBLL's competition here
ABMD vs SIBN Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SIBN has a market cap of 617.3M. Regarding current trading prices, ABMD is priced at $381.02, while SIBN trades at $14.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SIBN's P/E ratio is -35.69. In terms of profitability, ABMD's ROE is +0.10%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, ABMD is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check SIBN's competition here
ABMD vs SRDX Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ABMD is priced at $381.02, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ABMD's ROE is +0.10%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, ABMD is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check SRDX's competition here
ABMD vs APEN Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ABMD is priced at $381.02, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas APEN's P/E ratio is -9.43. In terms of profitability, ABMD's ROE is +0.10%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ABMD is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check APEN's competition here
ABMD vs BVS Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BVS has a market cap of 579.2M. Regarding current trading prices, ABMD is priced at $381.02, while BVS trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BVS's P/E ratio is 20.85. In terms of profitability, ABMD's ROE is +0.10%, compared to BVS's ROE of +0.16%. Regarding short-term risk, ABMD is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check BVS's competition here
ABMD vs BWAY Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BWAY has a market cap of 550.7M. Regarding current trading prices, ABMD is priced at $381.02, while BWAY trades at $14.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BWAY's P/E ratio is 63.82. In terms of profitability, ABMD's ROE is +0.10%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, ABMD is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check BWAY's competition here
ABMD vs TCMD Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, TCMD has a market cap of 549.7M. Regarding current trading prices, ABMD is priced at $381.02, while TCMD trades at $25.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas TCMD's P/E ratio is 28.01. In terms of profitability, ABMD's ROE is +0.10%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, ABMD is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check TCMD's competition here
ABMD vs NPCE Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, NPCE has a market cap of 541.4M. Regarding current trading prices, ABMD is priced at $381.02, while NPCE trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas NPCE's P/E ratio is -24.43. In terms of profitability, ABMD's ROE is +0.10%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, ABMD is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check NPCE's competition here
ABMD vs ZIMV Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ABMD is priced at $381.02, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ABMD's ROE is +0.10%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, ABMD is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check ZIMV's competition here
ABMD vs CERS Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CERS has a market cap of 533M. Regarding current trading prices, ABMD is priced at $381.02, while CERS trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CERS's P/E ratio is -53.20. In terms of profitability, ABMD's ROE is +0.10%, compared to CERS's ROE of -0.15%. Regarding short-term risk, ABMD is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check CERS's competition here
ABMD vs CTKB Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CTKB has a market cap of 523M. Regarding current trading prices, ABMD is priced at $381.02, while CTKB trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CTKB's P/E ratio is -6.98. In terms of profitability, ABMD's ROE is +0.10%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, ABMD is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check CTKB's competition here
ABMD vs PACB Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PACB has a market cap of 490.8M. Regarding current trading prices, ABMD is priced at $381.02, while PACB trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PACB's P/E ratio is -3.85. In terms of profitability, ABMD's ROE is +0.10%, compared to PACB's ROE of -4.88%. Regarding short-term risk, ABMD is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check PACB's competition here
ABMD vs PMI Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PMI has a market cap of 476.9M. Regarding current trading prices, ABMD is priced at $381.02, while PMI trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PMI's P/E ratio is -0.40. In terms of profitability, ABMD's ROE is +0.10%, compared to PMI's ROE of +4.99%. Regarding short-term risk, ABMD is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check PMI's competition here
ABMD vs LAB Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, LAB has a market cap of 445M. Regarding current trading prices, ABMD is priced at $381.02, while LAB trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas LAB's P/E ratio is -8.77. In terms of profitability, ABMD's ROE is +0.10%, compared to LAB's ROE of -0.21%. Regarding short-term risk, ABMD is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check LAB's competition here
ABMD vs KIDS Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, KIDS has a market cap of 434.6M. Regarding current trading prices, ABMD is priced at $381.02, while KIDS trades at $18.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas KIDS's P/E ratio is -10.07. In terms of profitability, ABMD's ROE is +0.10%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, ABMD is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check KIDS's competition here
ABMD vs VREX Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, VREX has a market cap of 427.7M. Regarding current trading prices, ABMD is priced at $381.02, while VREX trades at $10.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas VREX's P/E ratio is -5.08. In terms of profitability, ABMD's ROE is +0.10%, compared to VREX's ROE of -0.18%. Regarding short-term risk, ABMD is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check VREX's competition here
ABMD vs CLPT Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CLPT has a market cap of 398.9M. Regarding current trading prices, ABMD is priced at $381.02, while CLPT trades at $14.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CLPT's P/E ratio is -13.30. In terms of profitability, ABMD's ROE is +0.10%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, ABMD is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check CLPT's competition here
ABMD vs OFIX Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, OFIX has a market cap of 392.9M. Regarding current trading prices, ABMD is priced at $381.02, while OFIX trades at $10.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas OFIX's P/E ratio is -6.48. In terms of profitability, ABMD's ROE is +0.10%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, ABMD is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check OFIX's competition here
ABMD vs VMD Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, VMD has a market cap of 366.5M. Regarding current trading prices, ABMD is priced at $381.02, while VMD trades at $9.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas VMD's P/E ratio is 25.84. In terms of profitability, ABMD's ROE is +0.10%, compared to VMD's ROE of +0.11%. Regarding short-term risk, ABMD is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check VMD's competition here
ABMD vs DCTH Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, DCTH has a market cap of 356.6M. Regarding current trading prices, ABMD is priced at $381.02, while DCTH trades at $10.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas DCTH's P/E ratio is 1033.00. In terms of profitability, ABMD's ROE is +0.10%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, ABMD is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check DCTH's competition here
ABMD vs AVR Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AVR has a market cap of 329.3M. Regarding current trading prices, ABMD is priced at $381.02, while AVR trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AVR's P/E ratio is -4.03. In terms of profitability, ABMD's ROE is +0.10%, compared to AVR's ROE of -1.24%. Regarding short-term risk, ABMD is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check AVR's competition here
ABMD vs MASS Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, MASS has a market cap of 327.5M. Regarding current trading prices, ABMD is priced at $381.02, while MASS trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas MASS's P/E ratio is -8.93. In terms of profitability, ABMD's ROE is +0.10%, compared to MASS's ROE of -0.26%. Regarding short-term risk, ABMD is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check MASS's competition here
ABMD vs SMLR Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ABMD is priced at $381.02, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ABMD's ROE is +0.10%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, ABMD is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check SMLR's competition here
ABMD vs ELMD Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ELMD has a market cap of 296.1M. Regarding current trading prices, ABMD is priced at $381.02, while ELMD trades at $36.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ELMD's P/E ratio is 30.56. In terms of profitability, ABMD's ROE is +0.10%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, ABMD is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check ELMD's competition here
ABMD vs SENS Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SENS has a market cap of 280.7M. Regarding current trading prices, ABMD is priced at $381.02, while SENS trades at $6.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SENS's P/E ratio is -3.41. In terms of profitability, ABMD's ROE is +0.10%, compared to SENS's ROE of -1.30%. Regarding short-term risk, ABMD is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check SENS's competition here
ABMD vs CATX Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CATX has a market cap of 273.5M. Regarding current trading prices, ABMD is priced at $381.02, while CATX trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CATX's P/E ratio is -2.51. In terms of profitability, ABMD's ROE is +0.10%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ABMD is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check CATX's competition here
ABMD vs MGRM Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ABMD is priced at $381.02, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas MGRM's P/E ratio is -11.11. In terms of profitability, ABMD's ROE is +0.10%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, ABMD is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check MGRM's competition here
ABMD vs SGHT Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SGHT has a market cap of 236.1M. Regarding current trading prices, ABMD is priced at $381.02, while SGHT trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SGHT's P/E ratio is -6.20. In terms of profitability, ABMD's ROE is +0.10%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, ABMD is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check SGHT's competition here
ABMD vs NVRO Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ABMD is priced at $381.02, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ABMD's ROE is +0.10%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ABMD is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check NVRO's competition here
ABMD vs TMCI Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, TMCI has a market cap of 220.6M. Regarding current trading prices, ABMD is priced at $381.02, while TMCI trades at $3.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas TMCI's P/E ratio is -3.54. In terms of profitability, ABMD's ROE is +0.10%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, ABMD is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check TMCI's competition here
ABMD vs EYES Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, ABMD is priced at $381.02, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas EYES's P/E ratio is N/A. In terms of profitability, ABMD's ROE is +0.10%, compared to EYES's ROE of -2.64%. Regarding short-term risk, ABMD is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check EYES's competition here
ABMD vs RXST Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, RXST has a market cap of 198.3M. Regarding current trading prices, ABMD is priced at $381.02, while RXST trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas RXST's P/E ratio is -4.24. In terms of profitability, ABMD's ROE is +0.10%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ABMD is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check RXST's competition here
ABMD vs PROF Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PROF has a market cap of 198.2M. Regarding current trading prices, ABMD is priced at $381.02, while PROF trades at $6.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PROF's P/E ratio is -5.28. In terms of profitability, ABMD's ROE is +0.10%, compared to PROF's ROE of -0.71%. Regarding short-term risk, ABMD is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check PROF's competition here
ABMD vs ANIK Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ANIK has a market cap of 191.7M. Regarding current trading prices, ABMD is priced at $381.02, while ANIK trades at $14.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ANIK's P/E ratio is -18.24. In terms of profitability, ABMD's ROE is +0.10%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, ABMD is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check ANIK's competition here
ABMD vs BSGM Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ABMD is priced at $381.02, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ABMD's ROE is +0.10%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, ABMD is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check BSGM's competition here
ABMD vs MDGS Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ABMD is priced at $381.02, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ABMD's ROE is +0.10%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ABMD is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check MDGS's competition here
ABMD vs EDAP Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, ABMD is priced at $381.02, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas EDAP's P/E ratio is -5.80. In terms of profitability, ABMD's ROE is +0.10%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, ABMD is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check EDAP's competition here
ABMD vs QTRX Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, QTRX has a market cap of 166.3M. Regarding current trading prices, ABMD is priced at $381.02, while QTRX trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas QTRX's P/E ratio is -1.50. In terms of profitability, ABMD's ROE is +0.10%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, ABMD is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check QTRX's competition here
ABMD vs QIPT Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ABMD is priced at $381.02, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ABMD's ROE is +0.10%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ABMD is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for ABMD.Check QIPT's competition here
ABMD vs INGN Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, INGN has a market cap of 161.9M. Regarding current trading prices, ABMD is priced at $381.02, while INGN trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas INGN's P/E ratio is -6.57. In terms of profitability, ABMD's ROE is +0.10%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ABMD is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check INGN's competition here
ABMD vs APYX Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, APYX has a market cap of 158.7M. Regarding current trading prices, ABMD is priced at $381.02, while APYX trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas APYX's P/E ratio is -17.23. In terms of profitability, ABMD's ROE is +0.10%, compared to APYX's ROE of -0.91%. Regarding short-term risk, ABMD is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check APYX's competition here
ABMD vs CVRX Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CVRX has a market cap of 143M. Regarding current trading prices, ABMD is priced at $381.02, while CVRX trades at $5.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CVRX's P/E ratio is -2.68. In terms of profitability, ABMD's ROE is +0.10%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, ABMD is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check CVRX's competition here
ABMD vs SNWV Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SNWV has a market cap of 134.1M. Regarding current trading prices, ABMD is priced at $381.02, while SNWV trades at $15.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SNWV's P/E ratio is 16.25. In terms of profitability, ABMD's ROE is +0.10%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, ABMD is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check SNWV's competition here
ABMD vs NNOX Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, NNOX has a market cap of 130.1M. Regarding current trading prices, ABMD is priced at $381.02, while NNOX trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas NNOX's P/E ratio is -1.61. In terms of profitability, ABMD's ROE is +0.10%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, ABMD is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check NNOX's competition here
ABMD vs MXCT Comparison June 2026
ABMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, MXCT has a market cap of 128.5M. Regarding current trading prices, ABMD is priced at $381.02, while MXCT trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas MXCT's P/E ratio is -3.33. In terms of profitability, ABMD's ROE is +0.10%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, ABMD is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for ABMD.Check MXCT's competition here